Global Oocyte Cryopreservation Market

Oocyte Cryopreservation Comprehensive Study by Type (Slow-cooling Method, Flash-freezing Process (Vitrification)), Application (25-30-Year-Old Female, 30-35-Year-Old Female, 35-40-Year-Old Female, Others), Component (Cryopreservation Media, Cryopreservation Storage Devices (Dewars, Cryogenic Liquid Cylinders, Cryogenic Storage Tanks, and Storage Container), Consumables & Accessories, Cryo-Shipping), End User (Biobanks, IVF & Fertility Clinics, Research & Academic Institutes, Cryo-shipping/couriers, Cryo Monitoring /Inventory Management) Players and Region - Global Market Outlook to 2028

Oocyte Cryopreservation Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Oocyte Cryopreservation?
Oocyte cryopreservation is a promising adjunct to human-assisted reproductive technology. Slow rate freezing has been the cryopreservation standard for the storage of sperm, embryos, and, subsequently, oocytes. Moreover, many studies indicated that acceptable oocyte survival, in vitro fertilization, normal embryos, and adequate blastocyst development can be achieved with oocyte cryopreservation, this has projected the growth of the global oocyte cryopreservation market in the forecast period.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledAnova Fertility (Canada), Manchester Fertility (United Kingdom), CCRM IVF (United States), CREATE Fertility (United Kingdom), Extend Fertility (United States), Kindbody (United States), HRC Fertility (United States), London Women's Clinic (United Kingdom), IVF Australia (Australia) and Prelude Fertility (United States)


The study covers a detailed analysis segmented by key business segments i.e. by type (Slow-cooling Method and Flash-freezing Process (Vitrification)) , by application (25-30-Year-Old Female, 30-35-Year-Old Female, 35-40-Year-Old Female and Others) and major geographies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Oocyte Cryopreservation market throughout the predicted period.

The competition is expected to become even more intense in the years to come due to the entry of several new players in the market. To help clients improve their revenue shares in the market, this research study provides an in-depth analysis of the market’s competitive landscape and offers information on the products offered by various leading companies. Additionally, this Oocyte Cryopreservation market report suggests strategies that Players can follow and highlights key areas they should focus on, in order to take maximum benefits of growth opportunities.

The report offers several leading Players, some of them are Anova Fertility (Canada), Manchester Fertility (United Kingdom), CCRM IVF (United States), CREATE Fertility (United Kingdom), Extend Fertility (United States), Kindbody (United States), HRC Fertility (United States), London Women's Clinic (United Kingdom), IVF Australia (Australia) and Prelude Fertility (United States).

Market Overview:
In Aug. 2022 CCRM Fertility, a global pioneer in fertility treatment, research and science, today announced the acquisition of The Institute for Reproductive Medicine & Science (IRMS), a fertility center with 11 reproductive endocrinologists and eight offices throughout New Jersey and New York. The strategic addition of IRMS furthers CCRM Fertility's growth trajectory and brings its world-class proprietary reproductive medicine expertise to IRMS offices and patients. CCRM Fertility will now serve 11 major metropolitan areas with 34 locations across the U.S. and Canada.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.

Influencing Trend:
Advancements in Freezing technology are Likely to Increase the Use of Donor Eggs, Sperm, or Embryo for Fertility Treatment

Market Growth Drivers:
Increasing Number of Egg, Sperm, or Embryo Donors, Raising Awareness about the Procedure among Individuals and Growing Numbers of Women Undergo Oocyte Cryopreservation for Both Medical and Social Reasons

Challenges:
Ice Formation and Damage to Oocyte Cryopreservation and Low Awareness about Cryogenic Offerings in Developing Countries and Rural Areas

Restraints:
High Cost Associated with Oocyte Cryopreservation

Opportunities:
Increased Emphasis on R&D Investments and Drug Discovery, Several Small Companies have Resorted to Outsourcing their Drug Discovery Process to Subcontract Laboratories

Key highlights of the Global Oocyte Cryopreservation market Study:
• CAGR of the market during the forecast period 2022-2028
• In-depth information on growth factors that will accelerate the Oocyte Cryopreservation market in next few years.
• Detailed Insights on futuristic trends and changing consumer behavior
• Forecast of the Global Oocyte Cryopreservation market size and its contribution to the parent market by type, application and by country.
• A broad view of customer demand
• Uncover market’s competitive landscape and in-depth information on various Players
• Comprehensive information about factors that will challenge the growth of Oocyte Cryopreservation Players

Transformation and Important Triggers:
Business transformation has taken hold across the broad corporate landscape due to the confluence of several important triggers, including:
• A tipping point in globalization
• A major slowdown in Western economies
• Significant shifts in technology and cost structure
• The challenges of regulatory compliance
• New forms of competition developing

Research Methodology:

The top-down and bottom-up approaches are used to estimate and validate the size of the Global Oocyte Cryopreservation market.
In order to reach an exhaustive list of functional and relevant players, various industry classification standards are closely followed such as NAICS, ICB, and SIC to penetrate deep into important geographies by players, and a thorough validation test is conducted to reach the most relevant players for survey in Oocyte Cryopreservation market.
In order to make a priority list sorting is done based on revenue generated based on the latest reporting, using paid databases such as Factiva, Bloomberg, etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment> by targeting key target audience that includes Oocyte Cryopreservation Providers, Research Organizations and Consulting Companies, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors, End Users and Others.
This helps us to gather the data for the players’ revenue, operating cycle and expense, profit along with product or service growth, etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that include Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases, etc.

Report Objectives / Segmentation Covered

By Type
  • Slow-cooling Method
  • Flash-freezing Process (Vitrification)
By Application
  • 25-30-Year-Old Female
  • 30-35-Year-Old Female
  • 35-40-Year-Old Female
  • Others
By Component
  • Cryopreservation Media
  • Cryopreservation Storage Devices (Dewars, Cryogenic Liquid Cylinders, Cryogenic Storage Tanks, and Storage Container)
  • Consumables & Accessories
  • Cryo-Shipping

By End User
  • Biobanks
  • IVF & Fertility Clinics
  • Research & Academic Institutes
  • Cryo-shipping/couriers
  • Cryo Monitoring /Inventory Management

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Number of Egg, Sperm, or Embryo Donors
      • 3.2.2. Raising Awareness about the Procedure among Individuals
      • 3.2.3. Growing Numbers of Women Undergo Oocyte Cryopreservation for Both Medical and Social Reasons
    • 3.3. Market Challenges
      • 3.3.1. Ice Formation and Damage to Oocyte Cryopreservation
      • 3.3.2. Low Awareness about Cryogenic Offerings in Developing Countries and Rural Areas
    • 3.4. Market Trends
      • 3.4.1. Advancements in Freezing technology are Likely to Increase the Use of Donor Eggs, Sperm, or Embryo for Fertility Treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Oocyte Cryopreservation, by Type, Application, Component, End User and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Oocyte Cryopreservation (Value)
      • 5.2.1. Global Oocyte Cryopreservation by: Type (Value)
        • 5.2.1.1. Slow-cooling Method
        • 5.2.1.2. Flash-freezing Process (Vitrification)
      • 5.2.2. Global Oocyte Cryopreservation by: Application (Value)
        • 5.2.2.1. 25-30-Year-Old Female
        • 5.2.2.2. 30-35-Year-Old Female
        • 5.2.2.3. 35-40-Year-Old Female
        • 5.2.2.4. Others
      • 5.2.3. Global Oocyte Cryopreservation by: Component (Value)
        • 5.2.3.1. Cryopreservation Media
        • 5.2.3.2. Cryopreservation Storage Devices (Dewars, Cryogenic Liquid Cylinders, Cryogenic Storage Tanks, and Storage Container)
        • 5.2.3.3. Consumables & Accessories
        • 5.2.3.4. Cryo-Shipping
      • 5.2.4. Global Oocyte Cryopreservation by: End User (Value)
        • 5.2.4.1. Biobanks
        • 5.2.4.2. IVF & Fertility Clinics
        • 5.2.4.3. Research & Academic Institutes
        • 5.2.4.4. Cryo-shipping/couriers
        • 5.2.4.5. Cryo Monitoring /Inventory Management
      • 5.2.5. Global Oocyte Cryopreservation Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Oocyte Cryopreservation: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Anova Fertility (Canada)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Manchester Fertility (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. CCRM IVF (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. CREATE Fertility (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Extend Fertility (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Kindbody (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. HRC Fertility (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. London Women's Clinic (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. IVF Australia (Australia)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Prelude Fertility (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Oocyte Cryopreservation Sale, by Type, Application, Component, End User and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Oocyte Cryopreservation (Value)
      • 7.2.1. Global Oocyte Cryopreservation by: Type (Value)
        • 7.2.1.1. Slow-cooling Method
        • 7.2.1.2. Flash-freezing Process (Vitrification)
      • 7.2.2. Global Oocyte Cryopreservation by: Application (Value)
        • 7.2.2.1. 25-30-Year-Old Female
        • 7.2.2.2. 30-35-Year-Old Female
        • 7.2.2.3. 35-40-Year-Old Female
        • 7.2.2.4. Others
      • 7.2.3. Global Oocyte Cryopreservation by: Component (Value)
        • 7.2.3.1. Cryopreservation Media
        • 7.2.3.2. Cryopreservation Storage Devices (Dewars, Cryogenic Liquid Cylinders, Cryogenic Storage Tanks, and Storage Container)
        • 7.2.3.3. Consumables & Accessories
        • 7.2.3.4. Cryo-Shipping
      • 7.2.4. Global Oocyte Cryopreservation by: End User (Value)
        • 7.2.4.1. Biobanks
        • 7.2.4.2. IVF & Fertility Clinics
        • 7.2.4.3. Research & Academic Institutes
        • 7.2.4.4. Cryo-shipping/couriers
        • 7.2.4.5. Cryo Monitoring /Inventory Management
      • 7.2.5. Global Oocyte Cryopreservation Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Oocyte Cryopreservation: by Type(USD Million)
  • Table 2. Oocyte Cryopreservation Slow-cooling Method , by Region USD Million (2017-2022)
  • Table 3. Oocyte Cryopreservation Flash-freezing Process (Vitrification) , by Region USD Million (2017-2022)
  • Table 4. Oocyte Cryopreservation: by Application(USD Million)
  • Table 5. Oocyte Cryopreservation 25-30-Year-Old Female , by Region USD Million (2017-2022)
  • Table 6. Oocyte Cryopreservation 30-35-Year-Old Female , by Region USD Million (2017-2022)
  • Table 7. Oocyte Cryopreservation 35-40-Year-Old Female , by Region USD Million (2017-2022)
  • Table 8. Oocyte Cryopreservation Others , by Region USD Million (2017-2022)
  • Table 9. Oocyte Cryopreservation: by Component(USD Million)
  • Table 10. Oocyte Cryopreservation Cryopreservation Media , by Region USD Million (2017-2022)
  • Table 11. Oocyte Cryopreservation Cryopreservation Storage Devices (Dewars, Cryogenic Liquid Cylinders, Cryogenic Storage Tanks, and Storage Container) , by Region USD Million (2017-2022)
  • Table 12. Oocyte Cryopreservation Consumables & Accessories , by Region USD Million (2017-2022)
  • Table 13. Oocyte Cryopreservation Cryo-Shipping , by Region USD Million (2017-2022)
  • Table 14. Oocyte Cryopreservation: by End User(USD Million)
  • Table 15. Oocyte Cryopreservation Biobanks , by Region USD Million (2017-2022)
  • Table 16. Oocyte Cryopreservation IVF & Fertility Clinics , by Region USD Million (2017-2022)
  • Table 17. Oocyte Cryopreservation Research & Academic Institutes , by Region USD Million (2017-2022)
  • Table 18. Oocyte Cryopreservation Cryo-shipping/couriers , by Region USD Million (2017-2022)
  • Table 19. Oocyte Cryopreservation Cryo Monitoring /Inventory Management , by Region USD Million (2017-2022)
  • Table 20. South America Oocyte Cryopreservation, by Country USD Million (2017-2022)
  • Table 21. South America Oocyte Cryopreservation, by Type USD Million (2017-2022)
  • Table 22. South America Oocyte Cryopreservation, by Application USD Million (2017-2022)
  • Table 23. South America Oocyte Cryopreservation, by Component USD Million (2017-2022)
  • Table 24. South America Oocyte Cryopreservation, by End User USD Million (2017-2022)
  • Table 25. Brazil Oocyte Cryopreservation, by Type USD Million (2017-2022)
  • Table 26. Brazil Oocyte Cryopreservation, by Application USD Million (2017-2022)
  • Table 27. Brazil Oocyte Cryopreservation, by Component USD Million (2017-2022)
  • Table 28. Brazil Oocyte Cryopreservation, by End User USD Million (2017-2022)
  • Table 29. Argentina Oocyte Cryopreservation, by Type USD Million (2017-2022)
  • Table 30. Argentina Oocyte Cryopreservation, by Application USD Million (2017-2022)
  • Table 31. Argentina Oocyte Cryopreservation, by Component USD Million (2017-2022)
  • Table 32. Argentina Oocyte Cryopreservation, by End User USD Million (2017-2022)
  • Table 33. Rest of South America Oocyte Cryopreservation, by Type USD Million (2017-2022)
  • Table 34. Rest of South America Oocyte Cryopreservation, by Application USD Million (2017-2022)
  • Table 35. Rest of South America Oocyte Cryopreservation, by Component USD Million (2017-2022)
  • Table 36. Rest of South America Oocyte Cryopreservation, by End User USD Million (2017-2022)
  • Table 37. Asia Pacific Oocyte Cryopreservation, by Country USD Million (2017-2022)
  • Table 38. Asia Pacific Oocyte Cryopreservation, by Type USD Million (2017-2022)
  • Table 39. Asia Pacific Oocyte Cryopreservation, by Application USD Million (2017-2022)
  • Table 40. Asia Pacific Oocyte Cryopreservation, by Component USD Million (2017-2022)
  • Table 41. Asia Pacific Oocyte Cryopreservation, by End User USD Million (2017-2022)
  • Table 42. China Oocyte Cryopreservation, by Type USD Million (2017-2022)
  • Table 43. China Oocyte Cryopreservation, by Application USD Million (2017-2022)
  • Table 44. China Oocyte Cryopreservation, by Component USD Million (2017-2022)
  • Table 45. China Oocyte Cryopreservation, by End User USD Million (2017-2022)
  • Table 46. Japan Oocyte Cryopreservation, by Type USD Million (2017-2022)
  • Table 47. Japan Oocyte Cryopreservation, by Application USD Million (2017-2022)
  • Table 48. Japan Oocyte Cryopreservation, by Component USD Million (2017-2022)
  • Table 49. Japan Oocyte Cryopreservation, by End User USD Million (2017-2022)
  • Table 50. India Oocyte Cryopreservation, by Type USD Million (2017-2022)
  • Table 51. India Oocyte Cryopreservation, by Application USD Million (2017-2022)
  • Table 52. India Oocyte Cryopreservation, by Component USD Million (2017-2022)
  • Table 53. India Oocyte Cryopreservation, by End User USD Million (2017-2022)
  • Table 54. South Korea Oocyte Cryopreservation, by Type USD Million (2017-2022)
  • Table 55. South Korea Oocyte Cryopreservation, by Application USD Million (2017-2022)
  • Table 56. South Korea Oocyte Cryopreservation, by Component USD Million (2017-2022)
  • Table 57. South Korea Oocyte Cryopreservation, by End User USD Million (2017-2022)
  • Table 58. Taiwan Oocyte Cryopreservation, by Type USD Million (2017-2022)
  • Table 59. Taiwan Oocyte Cryopreservation, by Application USD Million (2017-2022)
  • Table 60. Taiwan Oocyte Cryopreservation, by Component USD Million (2017-2022)
  • Table 61. Taiwan Oocyte Cryopreservation, by End User USD Million (2017-2022)
  • Table 62. Australia Oocyte Cryopreservation, by Type USD Million (2017-2022)
  • Table 63. Australia Oocyte Cryopreservation, by Application USD Million (2017-2022)
  • Table 64. Australia Oocyte Cryopreservation, by Component USD Million (2017-2022)
  • Table 65. Australia Oocyte Cryopreservation, by End User USD Million (2017-2022)
  • Table 66. Rest of Asia-Pacific Oocyte Cryopreservation, by Type USD Million (2017-2022)
  • Table 67. Rest of Asia-Pacific Oocyte Cryopreservation, by Application USD Million (2017-2022)
  • Table 68. Rest of Asia-Pacific Oocyte Cryopreservation, by Component USD Million (2017-2022)
  • Table 69. Rest of Asia-Pacific Oocyte Cryopreservation, by End User USD Million (2017-2022)
  • Table 70. Europe Oocyte Cryopreservation, by Country USD Million (2017-2022)
  • Table 71. Europe Oocyte Cryopreservation, by Type USD Million (2017-2022)
  • Table 72. Europe Oocyte Cryopreservation, by Application USD Million (2017-2022)
  • Table 73. Europe Oocyte Cryopreservation, by Component USD Million (2017-2022)
  • Table 74. Europe Oocyte Cryopreservation, by End User USD Million (2017-2022)
  • Table 75. Germany Oocyte Cryopreservation, by Type USD Million (2017-2022)
  • Table 76. Germany Oocyte Cryopreservation, by Application USD Million (2017-2022)
  • Table 77. Germany Oocyte Cryopreservation, by Component USD Million (2017-2022)
  • Table 78. Germany Oocyte Cryopreservation, by End User USD Million (2017-2022)
  • Table 79. France Oocyte Cryopreservation, by Type USD Million (2017-2022)
  • Table 80. France Oocyte Cryopreservation, by Application USD Million (2017-2022)
  • Table 81. France Oocyte Cryopreservation, by Component USD Million (2017-2022)
  • Table 82. France Oocyte Cryopreservation, by End User USD Million (2017-2022)
  • Table 83. Italy Oocyte Cryopreservation, by Type USD Million (2017-2022)
  • Table 84. Italy Oocyte Cryopreservation, by Application USD Million (2017-2022)
  • Table 85. Italy Oocyte Cryopreservation, by Component USD Million (2017-2022)
  • Table 86. Italy Oocyte Cryopreservation, by End User USD Million (2017-2022)
  • Table 87. United Kingdom Oocyte Cryopreservation, by Type USD Million (2017-2022)
  • Table 88. United Kingdom Oocyte Cryopreservation, by Application USD Million (2017-2022)
  • Table 89. United Kingdom Oocyte Cryopreservation, by Component USD Million (2017-2022)
  • Table 90. United Kingdom Oocyte Cryopreservation, by End User USD Million (2017-2022)
  • Table 91. Netherlands Oocyte Cryopreservation, by Type USD Million (2017-2022)
  • Table 92. Netherlands Oocyte Cryopreservation, by Application USD Million (2017-2022)
  • Table 93. Netherlands Oocyte Cryopreservation, by Component USD Million (2017-2022)
  • Table 94. Netherlands Oocyte Cryopreservation, by End User USD Million (2017-2022)
  • Table 95. Rest of Europe Oocyte Cryopreservation, by Type USD Million (2017-2022)
  • Table 96. Rest of Europe Oocyte Cryopreservation, by Application USD Million (2017-2022)
  • Table 97. Rest of Europe Oocyte Cryopreservation, by Component USD Million (2017-2022)
  • Table 98. Rest of Europe Oocyte Cryopreservation, by End User USD Million (2017-2022)
  • Table 99. MEA Oocyte Cryopreservation, by Country USD Million (2017-2022)
  • Table 100. MEA Oocyte Cryopreservation, by Type USD Million (2017-2022)
  • Table 101. MEA Oocyte Cryopreservation, by Application USD Million (2017-2022)
  • Table 102. MEA Oocyte Cryopreservation, by Component USD Million (2017-2022)
  • Table 103. MEA Oocyte Cryopreservation, by End User USD Million (2017-2022)
  • Table 104. Middle East Oocyte Cryopreservation, by Type USD Million (2017-2022)
  • Table 105. Middle East Oocyte Cryopreservation, by Application USD Million (2017-2022)
  • Table 106. Middle East Oocyte Cryopreservation, by Component USD Million (2017-2022)
  • Table 107. Middle East Oocyte Cryopreservation, by End User USD Million (2017-2022)
  • Table 108. Africa Oocyte Cryopreservation, by Type USD Million (2017-2022)
  • Table 109. Africa Oocyte Cryopreservation, by Application USD Million (2017-2022)
  • Table 110. Africa Oocyte Cryopreservation, by Component USD Million (2017-2022)
  • Table 111. Africa Oocyte Cryopreservation, by End User USD Million (2017-2022)
  • Table 112. North America Oocyte Cryopreservation, by Country USD Million (2017-2022)
  • Table 113. North America Oocyte Cryopreservation, by Type USD Million (2017-2022)
  • Table 114. North America Oocyte Cryopreservation, by Application USD Million (2017-2022)
  • Table 115. North America Oocyte Cryopreservation, by Component USD Million (2017-2022)
  • Table 116. North America Oocyte Cryopreservation, by End User USD Million (2017-2022)
  • Table 117. United States Oocyte Cryopreservation, by Type USD Million (2017-2022)
  • Table 118. United States Oocyte Cryopreservation, by Application USD Million (2017-2022)
  • Table 119. United States Oocyte Cryopreservation, by Component USD Million (2017-2022)
  • Table 120. United States Oocyte Cryopreservation, by End User USD Million (2017-2022)
  • Table 121. Canada Oocyte Cryopreservation, by Type USD Million (2017-2022)
  • Table 122. Canada Oocyte Cryopreservation, by Application USD Million (2017-2022)
  • Table 123. Canada Oocyte Cryopreservation, by Component USD Million (2017-2022)
  • Table 124. Canada Oocyte Cryopreservation, by End User USD Million (2017-2022)
  • Table 125. Mexico Oocyte Cryopreservation, by Type USD Million (2017-2022)
  • Table 126. Mexico Oocyte Cryopreservation, by Application USD Million (2017-2022)
  • Table 127. Mexico Oocyte Cryopreservation, by Component USD Million (2017-2022)
  • Table 128. Mexico Oocyte Cryopreservation, by End User USD Million (2017-2022)
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Oocyte Cryopreservation: by Type(USD Million)
  • Table 140. Oocyte Cryopreservation Slow-cooling Method , by Region USD Million (2023-2028)
  • Table 141. Oocyte Cryopreservation Flash-freezing Process (Vitrification) , by Region USD Million (2023-2028)
  • Table 142. Oocyte Cryopreservation: by Application(USD Million)
  • Table 143. Oocyte Cryopreservation 25-30-Year-Old Female , by Region USD Million (2023-2028)
  • Table 144. Oocyte Cryopreservation 30-35-Year-Old Female , by Region USD Million (2023-2028)
  • Table 145. Oocyte Cryopreservation 35-40-Year-Old Female , by Region USD Million (2023-2028)
  • Table 146. Oocyte Cryopreservation Others , by Region USD Million (2023-2028)
  • Table 147. Oocyte Cryopreservation: by Component(USD Million)
  • Table 148. Oocyte Cryopreservation Cryopreservation Media , by Region USD Million (2023-2028)
  • Table 149. Oocyte Cryopreservation Cryopreservation Storage Devices (Dewars, Cryogenic Liquid Cylinders, Cryogenic Storage Tanks, and Storage Container) , by Region USD Million (2023-2028)
  • Table 150. Oocyte Cryopreservation Consumables & Accessories , by Region USD Million (2023-2028)
  • Table 151. Oocyte Cryopreservation Cryo-Shipping , by Region USD Million (2023-2028)
  • Table 152. Oocyte Cryopreservation: by End User(USD Million)
  • Table 153. Oocyte Cryopreservation Biobanks , by Region USD Million (2023-2028)
  • Table 154. Oocyte Cryopreservation IVF & Fertility Clinics , by Region USD Million (2023-2028)
  • Table 155. Oocyte Cryopreservation Research & Academic Institutes , by Region USD Million (2023-2028)
  • Table 156. Oocyte Cryopreservation Cryo-shipping/couriers , by Region USD Million (2023-2028)
  • Table 157. Oocyte Cryopreservation Cryo Monitoring /Inventory Management , by Region USD Million (2023-2028)
  • Table 158. South America Oocyte Cryopreservation, by Country USD Million (2023-2028)
  • Table 159. South America Oocyte Cryopreservation, by Type USD Million (2023-2028)
  • Table 160. South America Oocyte Cryopreservation, by Application USD Million (2023-2028)
  • Table 161. South America Oocyte Cryopreservation, by Component USD Million (2023-2028)
  • Table 162. South America Oocyte Cryopreservation, by End User USD Million (2023-2028)
  • Table 163. Brazil Oocyte Cryopreservation, by Type USD Million (2023-2028)
  • Table 164. Brazil Oocyte Cryopreservation, by Application USD Million (2023-2028)
  • Table 165. Brazil Oocyte Cryopreservation, by Component USD Million (2023-2028)
  • Table 166. Brazil Oocyte Cryopreservation, by End User USD Million (2023-2028)
  • Table 167. Argentina Oocyte Cryopreservation, by Type USD Million (2023-2028)
  • Table 168. Argentina Oocyte Cryopreservation, by Application USD Million (2023-2028)
  • Table 169. Argentina Oocyte Cryopreservation, by Component USD Million (2023-2028)
  • Table 170. Argentina Oocyte Cryopreservation, by End User USD Million (2023-2028)
  • Table 171. Rest of South America Oocyte Cryopreservation, by Type USD Million (2023-2028)
  • Table 172. Rest of South America Oocyte Cryopreservation, by Application USD Million (2023-2028)
  • Table 173. Rest of South America Oocyte Cryopreservation, by Component USD Million (2023-2028)
  • Table 174. Rest of South America Oocyte Cryopreservation, by End User USD Million (2023-2028)
  • Table 175. Asia Pacific Oocyte Cryopreservation, by Country USD Million (2023-2028)
  • Table 176. Asia Pacific Oocyte Cryopreservation, by Type USD Million (2023-2028)
  • Table 177. Asia Pacific Oocyte Cryopreservation, by Application USD Million (2023-2028)
  • Table 178. Asia Pacific Oocyte Cryopreservation, by Component USD Million (2023-2028)
  • Table 179. Asia Pacific Oocyte Cryopreservation, by End User USD Million (2023-2028)
  • Table 180. China Oocyte Cryopreservation, by Type USD Million (2023-2028)
  • Table 181. China Oocyte Cryopreservation, by Application USD Million (2023-2028)
  • Table 182. China Oocyte Cryopreservation, by Component USD Million (2023-2028)
  • Table 183. China Oocyte Cryopreservation, by End User USD Million (2023-2028)
  • Table 184. Japan Oocyte Cryopreservation, by Type USD Million (2023-2028)
  • Table 185. Japan Oocyte Cryopreservation, by Application USD Million (2023-2028)
  • Table 186. Japan Oocyte Cryopreservation, by Component USD Million (2023-2028)
  • Table 187. Japan Oocyte Cryopreservation, by End User USD Million (2023-2028)
  • Table 188. India Oocyte Cryopreservation, by Type USD Million (2023-2028)
  • Table 189. India Oocyte Cryopreservation, by Application USD Million (2023-2028)
  • Table 190. India Oocyte Cryopreservation, by Component USD Million (2023-2028)
  • Table 191. India Oocyte Cryopreservation, by End User USD Million (2023-2028)
  • Table 192. South Korea Oocyte Cryopreservation, by Type USD Million (2023-2028)
  • Table 193. South Korea Oocyte Cryopreservation, by Application USD Million (2023-2028)
  • Table 194. South Korea Oocyte Cryopreservation, by Component USD Million (2023-2028)
  • Table 195. South Korea Oocyte Cryopreservation, by End User USD Million (2023-2028)
  • Table 196. Taiwan Oocyte Cryopreservation, by Type USD Million (2023-2028)
  • Table 197. Taiwan Oocyte Cryopreservation, by Application USD Million (2023-2028)
  • Table 198. Taiwan Oocyte Cryopreservation, by Component USD Million (2023-2028)
  • Table 199. Taiwan Oocyte Cryopreservation, by End User USD Million (2023-2028)
  • Table 200. Australia Oocyte Cryopreservation, by Type USD Million (2023-2028)
  • Table 201. Australia Oocyte Cryopreservation, by Application USD Million (2023-2028)
  • Table 202. Australia Oocyte Cryopreservation, by Component USD Million (2023-2028)
  • Table 203. Australia Oocyte Cryopreservation, by End User USD Million (2023-2028)
  • Table 204. Rest of Asia-Pacific Oocyte Cryopreservation, by Type USD Million (2023-2028)
  • Table 205. Rest of Asia-Pacific Oocyte Cryopreservation, by Application USD Million (2023-2028)
  • Table 206. Rest of Asia-Pacific Oocyte Cryopreservation, by Component USD Million (2023-2028)
  • Table 207. Rest of Asia-Pacific Oocyte Cryopreservation, by End User USD Million (2023-2028)
  • Table 208. Europe Oocyte Cryopreservation, by Country USD Million (2023-2028)
  • Table 209. Europe Oocyte Cryopreservation, by Type USD Million (2023-2028)
  • Table 210. Europe Oocyte Cryopreservation, by Application USD Million (2023-2028)
  • Table 211. Europe Oocyte Cryopreservation, by Component USD Million (2023-2028)
  • Table 212. Europe Oocyte Cryopreservation, by End User USD Million (2023-2028)
  • Table 213. Germany Oocyte Cryopreservation, by Type USD Million (2023-2028)
  • Table 214. Germany Oocyte Cryopreservation, by Application USD Million (2023-2028)
  • Table 215. Germany Oocyte Cryopreservation, by Component USD Million (2023-2028)
  • Table 216. Germany Oocyte Cryopreservation, by End User USD Million (2023-2028)
  • Table 217. France Oocyte Cryopreservation, by Type USD Million (2023-2028)
  • Table 218. France Oocyte Cryopreservation, by Application USD Million (2023-2028)
  • Table 219. France Oocyte Cryopreservation, by Component USD Million (2023-2028)
  • Table 220. France Oocyte Cryopreservation, by End User USD Million (2023-2028)
  • Table 221. Italy Oocyte Cryopreservation, by Type USD Million (2023-2028)
  • Table 222. Italy Oocyte Cryopreservation, by Application USD Million (2023-2028)
  • Table 223. Italy Oocyte Cryopreservation, by Component USD Million (2023-2028)
  • Table 224. Italy Oocyte Cryopreservation, by End User USD Million (2023-2028)
  • Table 225. United Kingdom Oocyte Cryopreservation, by Type USD Million (2023-2028)
  • Table 226. United Kingdom Oocyte Cryopreservation, by Application USD Million (2023-2028)
  • Table 227. United Kingdom Oocyte Cryopreservation, by Component USD Million (2023-2028)
  • Table 228. United Kingdom Oocyte Cryopreservation, by End User USD Million (2023-2028)
  • Table 229. Netherlands Oocyte Cryopreservation, by Type USD Million (2023-2028)
  • Table 230. Netherlands Oocyte Cryopreservation, by Application USD Million (2023-2028)
  • Table 231. Netherlands Oocyte Cryopreservation, by Component USD Million (2023-2028)
  • Table 232. Netherlands Oocyte Cryopreservation, by End User USD Million (2023-2028)
  • Table 233. Rest of Europe Oocyte Cryopreservation, by Type USD Million (2023-2028)
  • Table 234. Rest of Europe Oocyte Cryopreservation, by Application USD Million (2023-2028)
  • Table 235. Rest of Europe Oocyte Cryopreservation, by Component USD Million (2023-2028)
  • Table 236. Rest of Europe Oocyte Cryopreservation, by End User USD Million (2023-2028)
  • Table 237. MEA Oocyte Cryopreservation, by Country USD Million (2023-2028)
  • Table 238. MEA Oocyte Cryopreservation, by Type USD Million (2023-2028)
  • Table 239. MEA Oocyte Cryopreservation, by Application USD Million (2023-2028)
  • Table 240. MEA Oocyte Cryopreservation, by Component USD Million (2023-2028)
  • Table 241. MEA Oocyte Cryopreservation, by End User USD Million (2023-2028)
  • Table 242. Middle East Oocyte Cryopreservation, by Type USD Million (2023-2028)
  • Table 243. Middle East Oocyte Cryopreservation, by Application USD Million (2023-2028)
  • Table 244. Middle East Oocyte Cryopreservation, by Component USD Million (2023-2028)
  • Table 245. Middle East Oocyte Cryopreservation, by End User USD Million (2023-2028)
  • Table 246. Africa Oocyte Cryopreservation, by Type USD Million (2023-2028)
  • Table 247. Africa Oocyte Cryopreservation, by Application USD Million (2023-2028)
  • Table 248. Africa Oocyte Cryopreservation, by Component USD Million (2023-2028)
  • Table 249. Africa Oocyte Cryopreservation, by End User USD Million (2023-2028)
  • Table 250. North America Oocyte Cryopreservation, by Country USD Million (2023-2028)
  • Table 251. North America Oocyte Cryopreservation, by Type USD Million (2023-2028)
  • Table 252. North America Oocyte Cryopreservation, by Application USD Million (2023-2028)
  • Table 253. North America Oocyte Cryopreservation, by Component USD Million (2023-2028)
  • Table 254. North America Oocyte Cryopreservation, by End User USD Million (2023-2028)
  • Table 255. United States Oocyte Cryopreservation, by Type USD Million (2023-2028)
  • Table 256. United States Oocyte Cryopreservation, by Application USD Million (2023-2028)
  • Table 257. United States Oocyte Cryopreservation, by Component USD Million (2023-2028)
  • Table 258. United States Oocyte Cryopreservation, by End User USD Million (2023-2028)
  • Table 259. Canada Oocyte Cryopreservation, by Type USD Million (2023-2028)
  • Table 260. Canada Oocyte Cryopreservation, by Application USD Million (2023-2028)
  • Table 261. Canada Oocyte Cryopreservation, by Component USD Million (2023-2028)
  • Table 262. Canada Oocyte Cryopreservation, by End User USD Million (2023-2028)
  • Table 263. Mexico Oocyte Cryopreservation, by Type USD Million (2023-2028)
  • Table 264. Mexico Oocyte Cryopreservation, by Application USD Million (2023-2028)
  • Table 265. Mexico Oocyte Cryopreservation, by Component USD Million (2023-2028)
  • Table 266. Mexico Oocyte Cryopreservation, by End User USD Million (2023-2028)
  • Table 267. Research Programs/Design for This Report
  • Table 268. Key Data Information from Secondary Sources
  • Table 269. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Oocyte Cryopreservation: by Type USD Million (2017-2022)
  • Figure 5. Global Oocyte Cryopreservation: by Application USD Million (2017-2022)
  • Figure 6. Global Oocyte Cryopreservation: by Component USD Million (2017-2022)
  • Figure 7. Global Oocyte Cryopreservation: by End User USD Million (2017-2022)
  • Figure 8. South America Oocyte Cryopreservation Share (%), by Country
  • Figure 9. Asia Pacific Oocyte Cryopreservation Share (%), by Country
  • Figure 10. Europe Oocyte Cryopreservation Share (%), by Country
  • Figure 11. MEA Oocyte Cryopreservation Share (%), by Country
  • Figure 12. North America Oocyte Cryopreservation Share (%), by Country
  • Figure 13. Global Oocyte Cryopreservation share by Players 2022 (%)
  • Figure 14. Global Oocyte Cryopreservation share by Players (Top 3) 2022(%)
  • Figure 15. Global Oocyte Cryopreservation share by Players (Top 5) 2022(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Anova Fertility (Canada) Revenue, Net Income and Gross profit
  • Figure 18. Anova Fertility (Canada) Revenue: by Geography 2022
  • Figure 19. Manchester Fertility (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 20. Manchester Fertility (United Kingdom) Revenue: by Geography 2022
  • Figure 21. CCRM IVF (United States) Revenue, Net Income and Gross profit
  • Figure 22. CCRM IVF (United States) Revenue: by Geography 2022
  • Figure 23. CREATE Fertility (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 24. CREATE Fertility (United Kingdom) Revenue: by Geography 2022
  • Figure 25. Extend Fertility (United States) Revenue, Net Income and Gross profit
  • Figure 26. Extend Fertility (United States) Revenue: by Geography 2022
  • Figure 27. Kindbody (United States) Revenue, Net Income and Gross profit
  • Figure 28. Kindbody (United States) Revenue: by Geography 2022
  • Figure 29. HRC Fertility (United States) Revenue, Net Income and Gross profit
  • Figure 30. HRC Fertility (United States) Revenue: by Geography 2022
  • Figure 31. London Women's Clinic (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 32. London Women's Clinic (United Kingdom) Revenue: by Geography 2022
  • Figure 33. IVF Australia (Australia) Revenue, Net Income and Gross profit
  • Figure 34. IVF Australia (Australia) Revenue: by Geography 2022
  • Figure 35. Prelude Fertility (United States) Revenue, Net Income and Gross profit
  • Figure 36. Prelude Fertility (United States) Revenue: by Geography 2022
  • Figure 37. Global Oocyte Cryopreservation: by Type USD Million (2023-2028)
  • Figure 38. Global Oocyte Cryopreservation: by Application USD Million (2023-2028)
  • Figure 39. Global Oocyte Cryopreservation: by Component USD Million (2023-2028)
  • Figure 40. Global Oocyte Cryopreservation: by End User USD Million (2023-2028)
  • Figure 41. South America Oocyte Cryopreservation Share (%), by Country
  • Figure 42. Asia Pacific Oocyte Cryopreservation Share (%), by Country
  • Figure 43. Europe Oocyte Cryopreservation Share (%), by Country
  • Figure 44. MEA Oocyte Cryopreservation Share (%), by Country
  • Figure 45. North America Oocyte Cryopreservation Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Anova Fertility (Canada)
  • Manchester Fertility (United Kingdom)
  • CCRM IVF (United States)
  • CREATE Fertility (United Kingdom)
  • Extend Fertility (United States)
  • Kindbody (United States)
  • HRC Fertility (United States)
  • London Women's Clinic (United Kingdom)
  • IVF Australia (Australia)
  • Prelude Fertility (United States)
Additional players considered in the study are as follows:
Reproductive Biology Associates (United States) , Virtus Health (Australia) , Mayo Clinic (United States) , Pacific Fertility Center-Los Angeles (PFCLA) (United States) , Monash IVF (Australia) , Shady Grove Fertility (United States) , Melbourne IVF (Australia) , San Diego Fertility Center (SDFC) (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 182 Pages 74 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Oocyte Cryopreservation Market Quantitative research analysis
Global Oocyte Cryopreservation Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Oocyte Cryopreservation Market is heading robustly to achieve a new growth cycle.
The Concentration Rate of Global Oocyte Cryopreservation market is dominated by United States Players and may generate healthy valuation by 2028.
  • Increasing Number of Egg, Sperm, or Embryo Donors
  • Raising Awareness about the Procedure among Individuals
  • Growing Numbers of Women Undergo Oocyte Cryopreservation for Both Medical and Social Reasons
dominated the Oocyte Cryopreservation market. This is attributable to growing trend of "Advancements in Freezing technology are Likely to Increase the Use of Donor Eggs, Sperm, or Embryo for Fertility Treatment"

Know More About Global Oocyte Cryopreservation Market Report?

Have a Query? Click Here

Other Related Reports

Wound Tissue Analysis Solutions Comprehensive Study by Application (Acute Wounds, Chronic Wounds, Burns, Ulcers, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacies, Mail Order Pharma...
$ 3650
Keratosis Pilaris Treatment Comprehensive Study by Type (Rubra, Alba, Rubra Faceii), Treatment (Over-The-Counter, Prescription Medication, Exfoliating, Laser Treatments), Sales Channel (Online Pharma...
$ 3500
Canine Lymphoma Treatment Comprehensive Study by Drug (Alkylating agents, Corticosteroids, Purine Analogs, Antimetabolites, Immune Modulators, Others), Lymphoma (Multicentric lymphoma, Alimentary lym...
$ 3650
Cardiac Arrest Treatment Comprehensive Study by Application (Hospital, Cardiac Clinics, Ambulatory Surgical Centers), Drug (Vasopressors, Anti-arrhythmic Drugs, Anticholinergic Drugs, Antihypertensiv...
$ 3650
Interstitial Lung Disease Treatment Comprehensive Study by Treatment (Antifibrotics, Corticosteroids, Cytotoxic Drugs, Lung Transplant, Oxygen Therapy, Pulmonary Rehabilitation, Others), End User (Ho...
$ 3350
Prokinetic Drugs Comprehensive Study by Type (Cisapride, Domperidone, Metoclopramide, Levosulpiride, Erythromycin, Tegaserod, Mosapride Citrate, Itopride hydrochloride, Renzapride, Prucalopride), App...
$ 3750